7

8 9

10 11

12

13

14

15 16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

Women Undergoing Third Line Overactive Bladder Treatment Demonstrate Elevated Thermal Temporal Summation

W. Stuart Reynolds,* Casey Kowalik, Joshua Cohn, Melissa Kaufman, Alan Wein, Roger Dmochowski and Stephen Bruehl

From the Departments of Urologic Surgery (WSR, CK, MK, RD) and Anesthesiology (SB), Vanderbilt University Medical Center, Nashville, Tennessee, and Department of Urology, Einstein Healthcare Network (JC) and Division of Urology, Department of Surgery, Perelman School of Medicine, University of Pennsylvania (AW), Philadelphia, Pennsylvania

	58
	00
	59
	60
	C1
	61
	62
	63
	61
	04
	65
	66
	67
	201
	68
	69
	70
	71
	11
	72
	73
	71
	14
	75
	76
	77
	••
	78
	79
	•••
	80
	80 81
	80 81
	80 81 82
	80 81 82 83
	80 81 82 83 84
	80 81 82 83 84
	80 81 82 83 84 85
	80 81 82 83 83 84 85 86
	80 81 82 83 84 85 86 87
	80 81 82 83 84 85 86 87
	80 81 82 83 84 85 86 87 88
	80 81 82 83 84 85 86 87 88 89
	80 81 82 83 84 85 86 87 88 89 90
	80 81 82 83 84 85 86 87 88 89 90 91
	80 81 82 83 84 85 86 87 88 89 90 91
	80 81 82 83 84 85 86 87 88 89 90 91 92
	80 81 82 83 84 85 86 87 88 89 90 91 92 93
	80 81 82 83 84 85 86 85 86 87 88 89 90 91 92 93 94
	80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95
	80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95
	80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96
	80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97
	80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98
	80 81 82 83 85 86 87 89 91 92 93 94 95 97 98
1	62366666666777777777787888888888899912939967999900

Purpose: We sought to determine whether women with overactive bladder who required third line therapy would demonstrate greater central sensitization, indexed by temporal summation to heat pain stimuli, than those with overactive bladder.

Materials and Methods: We recruited 39 women with overactive bladder from the urology clinic who were planning to undergo interventional therapy for medication refractory overactive bladder with onabotulinumtoxinA bladder injection or sacral neuromodulation. We also recruited 55 women with overactive bladder who were newly seen at our urology clinic or who responded to advertisements for study participation. Participants underwent quantitative sensory testing using a thermal temporal summation protocol. The primary study outcome was the degree of temporal summation as reflected in the magnitude of positive slope of the line fit to the series of 10 stimuli at a 49C target temperature. We compared the degree of temporal summation between the study groups using linear regression.

Results: Women in the group undergoing third line therapy showed significantly higher standardized temporal summation slopes than those in the nontreatment group ($\beta = 1.57, 95\%$ CI 0.18–2.96, t = 2.25, p = 0.027). On exploratory analyses a history of incontinence surgery or hysterectomy was associated with significantly greater temporal summation.

Conclusions: In this study the degree of temporal summation was elevated in women undergoing third line overactive bladder therapy compared to women with overactive bladder who were not undergoing that therapy. These findings suggest there may be pathophysiological differences, specifically in afferent nerve function and processing, in some women with overactive bladder.

Key Words: urinary bladder, overactive; urinary incontinence, urge; central nervous system sensitization; postsynaptic potential summation; patient reported outcome measures

OVERACTIVE bladder is a common condition affecting American women.¹ However, the etiology of OAB remains unclear and likely involves inherent elements of the bladder and functional aspects of motor and sensory nerve innervation.² In line with the afferent nerve hypothesis,² it is plausible that any condition which promotes increased responses to Abbreviations and Acronyms

CS = central sensitization ICIQ-FLUTS = International Consultation on Incontinence Modular Questionnaire-Female Lower Urinary Tract Symptoms OAB = overactive bladder OAB-q = OAB Questionnaire PROMIS = Patient-Reported Outcomes Measurement Information System TS = temporal summation VAS = visual analog scale

Accepted for publication April 29, 2018. No direct or indirect commercial incentive

associated with publishing this article. The corresponding author certifies that, when applicable, a statement(s) has been included in the manuscript documenting institutional review heard other committee or other prove

the manuscript documenting institutional review board, ethics committee or ethical review board study approval; principles of Helsinki Declaration were followed in lieu of formal ethics committee approval; institutional animal care and use committee approval; all human subjects provided written informed consent with guarantees of confidentiality; IRB approved protocol number; animal approved project number.

Supported by the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health Grant K23DK103910, the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction Foundation, and the National Center for Advancing Translational Sciences Grant UL1TR000445.

* Correspondence: Department of Urologic Surgery, A1302 Medical Center North, Vanderbilt University Medical Center, Nashville, Tennessee 37232 (telephone: 615-343-1317; FAX: 615-322-8990; e-mail: <u>w.stuart.reynolds@vumc.org</u>).

113

114

101

102

103

104

105

106

107

108

0022-5347/18/2004-0001/0

THE JOURNAL OF UROLOGY[®] © 2018 by American Urological Association Education and Research, Inc. https://doi.org/10.1016/j.juro.2018.05.007 Vol. 200, 1-6, October 2018 Printed in U.S.A.

www.jurology.com 1

OVERACTIVE BLADDER TREATMENT AND THERMAL TEMPORAL SUMMATION

normal or abnormal stimuli may contribute to the
development of or exacerbate existing OAB. We have
postulated that CS, a phenomenon well described in
the chronic pain literature in which afferent C-fiber
circuits display hyperresponsiveness,³ may have such
a role in certain individuals with OAB.¹

121We previously reported that compared to women 122without OAB those with OAB who required third 123line therapy with onabotulinumtoxinA bladder in-124jection or sacral neuromodulation showed greater 125thermal cutaneous TS, that is increasing perceived 126pain in response to rapid repetition of the same 127stimulus intensity.⁴ Because elevated TS is believed to be a marker for CS,^{5,6} this finding suggested 128elevated CS in patients with OAB when compared 129 130to nonOAB controls.

131Our current hypothesis was that CS may 132contribute to why some women with OAB are more 133likely than others to be refractory to first and second 134line OAB therapy. As the next step in this line of 135investigation, the aim of the current study was to 136determine whether women with OAB undergoing 137 third line therapy would show greater TS than 138women with OAB not undergoing these treatments. 139

MATERIALS AND METHODS

140

141

142After obtaining institutional review board approval we recruited 39 women 18 years old or older with OAB from the 143urology clinic who were planning to undergo onabotuli-144 numtoxinA bladder injection or sacral neuromodulation. We 145also recruited 55 women with OAB, which was confirmed by 146a score of 4 or greater on the OAB-V3 (OAB-Version 3) 147awareness tool,⁷ who were newly seen at our urology clinic 148or who responded to community advertisements and were 149not undergoing third line therapy.

150We excluded women from analysis if they were diag-151nosed with a neurological condition that might contribute 152to urinary symptoms (eg spinal cord injury, multiple sclerosis, stroke or autonomic dysfunction), had a history 153of bladder cancer, pelvic irradiation or bowel diversion, or 154were unable or unwilling to complete all study protocols. 155We also excluded women with interstitial cystitis/bladder 156pain syndrome based on medical record review and/or 157whether they met the RICE (Rand Interstitial Cystitis 158Epidemiology) case definition.⁸

159Participants completed a standardized questionnaire 160 assessing demographics and medical history, including 161age, race/ethnicity, highest education level, general 162health, prior history of incontinence surgery, hysterec-163tomy or prolapse surgery and whether they were receiving 164OAB medications. We assessed pelvic surgical history with yes or no questions, that is, "Have you ever had...?" a 165166 hysterectomy, an operation to remove the uterus or womb, or surgery for incontinence (urine leakage) or to repair 167 pelvic organ prolapse (pelvic floor disorder, cystocele or 168 rectocele). 169

Participants also completed the OAB-q⁹ and the ICIQ-FLUTS.¹⁰ To assess psychosocial and somatic characteristics they completed the NIH (National Institutes of Health) PROMIS short form, version 1.0 instruments for depression (8a), anxiety (8a) and pain intensity(3a) as well as the SSS-8 (Somatic Symptom Scale-8).¹¹ We also assessed the presence of comorbid functional somatic conditions by self-report (ie low back pain) or by validated patient reported diagnostic measures, including migraine headache,¹² fibromyalgia¹³ and irritable bowel syndrome.¹⁴

Quantitative Sensory Testing

All quantitative sensory testing protocols was done using a TSAII NeuroSensory Analyzer (Medoc, Minneapolis, Minnesota) with a 9 cm² Peltier thermode applied to the volar forearm. To determine heat pain threshold and tolerance levels we performed a series of 4 pain trials during which the probe temperature increased from a baseline temperature of 32C at a rate of 0.5C per second. In the heat pain threshold test the participant indicated the temperature at which the heat was first perceived as painful. In the heat pain tolerance trials the participant indicated when the pain became intolerable. We then separately derived the means of the 4 threshold and tolerance trials.

Our quantitative sensory techniques to measure TS are similar to those that are standard in the pain literature.^{6,15} They were previously detailed in the context of OAB.⁴ Briefly, we administered a sequence of 10 successive 0.5-second heat pulses to the forearm, during which the temperature rapidly increased and decreased from a temperature of 40C to 49C at a frequency of 0.4 Hz. This frequency is known to elicit C-fiber mediated temporal summation in the dorsal horn of the spinal cord. Immediately after the peak of every heat pulse the subjects provided a verbal numerical pain intensity rating using a VAS on a scale of 0—no pain or warmth to 100—worst possible pain. The standardized slope of the change in pain ratings over the series of 10 stimuli was derived for each patient as a TS index. A positive slope (greater than 0) indicated the presence of TS while a negative slope (less than 0) indicated habituation.

Statistical Analyses

Statistical analyses were performed with $Stata/SE^{TM}$ 14.1. We used the Student t-test to compare continuous variables and the chi-square test for categorical variables. Our independent variable in all primary analyses was the OAB group (OAB vs OAB undergoing third line therapy). We created linear regression models with the pain response index as the dependent variable (ie pain threshold, tolerance or TS), the OAB group as the independent variable, and patient age and the OQB-q score as control variables. To analyze TS we also included the initial VAS pain rating of the first TS stimulus to control for confounding due to baseline effects on observed slopes (ie ceiling effects). Finally, we explored possible factors that may have been be associated with the observed degree of TS using linear regression models in which the TS slope was the dependent variable. Analyses were done with 2-tailed p <0.05 considered statistically significant.

221

222

223

224

225

226

227

228

172

173

174

175

176

177

178

179

180

181

182

183

184

Download English Version:

https://daneshyari.com/en/article/10219392

Download Persian Version:

https://daneshyari.com/article/10219392

Daneshyari.com